Drugs / CART-GFRa4 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04877613 | Aug 2021 → Jun 2039 expected | medullary thyroid gland carcinoma | University of Pennsylvania | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-GFRa4 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04877613 ↗ |
| Modality | Cell therapy | “Intravenous infusion of lentiviral transduced autologous T cells that have been engineered” NCT04877613 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT04877613 ↗ |